Bio-Rad Laboratories (NYSE:BIO) said today it acquired Propel Labs high performance analytical flow cytometer platform, with a planned instrument launch from the acquisition later this year.
Flow cytometry is a technique used to identify and sort cells and their components, Hercules, Calif.-based Bio-Rad Laboratories said.
“We welcome the opportunity to expand our relationship with Propel Labs. The new instrument will complement our S3e™ Cell Sorter. When these instruments are combined with our antibody portfolio, Bio-Rad will offer researchers an unparalleled combination of ease and technology enabling greater insights into cellular mechanisms,” Bio-Rad life science group prez Shannon Hall said in a press release.
The platform can support a variety of platforms including immunology, phenotypic monitoring, cell signaling and stem cell research, the company said.
“This exciting new agreement builds on our already successful partnership with Bio-Rad. We are pleased to support Bio-Rad as it introduces an instrument that we believe will have a great impact in the area of cancer research,” Propel Labs CEO Tidhar Sadeh said in prepared remarks.
Last December, the former general counsel for Bio-Rad (NYSE:BIO) accused the company and CEO Norman Schwartz of firing him in retaliation for blowing the whistle on alleged violations of the Foreign Corrupt Practices Act in China.
Sanford Wadler, who was general counsel and executive vice president when Bio-Rad sacked him in June 2013, alleged that he was fired right before the company was slated to present findings from its investigation into bribery in Russia, Thailand and Vietnam. Bio-Rad later agreed to a $55 million settlement with the U.S. Justice Dept. and the Securities & Exchange Commission, which found that it paid $7.5 million in bribes to drum up some $35 million in profits.
